Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 240Gastrointestinal 9Gynecologic 8Head & Neck 7Other solid neoplasm 4Genitourinary 4CNS 4Breast 4Sarcoma 2Dermatologic 2Classical hematology 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 2Lung Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 2Carboplatin 2taxane 1romidepsin 1repotrectinib 1pralsetinib 1liposomal doxorubicin 1atezolizumab 1Vinorelbine 1Temozolomide 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Oxaliplatin 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lactones 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Etoposide 1Drug Therapy 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Cisplatin × NET × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡